Use of virus-like particles and nanoparticle-based vaccines for combating picornavirus infections

• Published in: Veterinary research (Paris) Vol. 55; no. 1; pp. 128 - 22
• Main Authors: Ren, Mei, Abdullah, Sahibzada Waheed, Pei, Chenchen, Guo, Huichen, Sun, Shiqi
• Format: Journal Article
• Language: English
• Published: England BioMed Central Ltd 30-09-2024; BioMed Central; BMC
• Subjects: adjuvant; Animals; Encephalitis; Genomes; Genomics; Health aspects; Hepatitis A; Immune response; Life Sciences; Medical research; Medicine, Experimental; Nanoparticles; Picornaviridae - immunology; Picornaviridae Infections - immunology; Picornaviridae Infections - prevention & control; Picornaviridae Infections - veterinary; picornavirus; Review; vaccine; Vaccines; Vaccines, Virus-Like Particle - immunology; Viral antigens; Viral proteins; Viral Vaccines - immunology; Virus-like particles; vaccine; nanoparticles; adjuvant; Virus-like particles; picornavirus
• ISSN: 1297-9716; 0928-4249; 1297-9716
• DOI: 10.1186/s13567-024-01383-x

Picornaviridae are non-enveloped ssRNA viruses that cause diseases such as poliomyelitis, hand-foot-and-mouth disease (HFMD), hepatitis A, encephalitis, myocarditis, and foot-and-mouth disease (FMD). Virus-like particles (VLPs) vaccines mainly comprise particles formed through the self-assembly of viral capsid proteins (for enveloped viruses, envelope proteins are also an option). They do not contain the viral genome. On the other hand, the nanoparticles vaccine (NPs) is mainly composed of self-assembling biological proteins or nanomaterials, with viral antigens displayed on the surface. The presentation of viral antigens on these particles in a repetitive array can elicit a strong immune response in animals. VLPs and NPs can be powerful platforms for multivalent antigen presentation. This review summarises the development of virus-like particle vaccines (VLPs) and nanoparticle vaccines (NPs) against picornaviruses. By detailing the progress made in the fight against various picornaviruses such as poliovirus (PV), foot-and-mouth disease virus (FMDV), enterovirus (EV), Senecavirus A (SVA), and encephalomyocarditis virus (EMCV), we in turn highlight the significant strides made in vaccine technology. These advancements include diverse construction methods, expression systems, elicited immune responses, and the use of various adjuvants. We see promising prospects for the continued development and optimisation of VLPs and NPs vaccines. Future research should focus on enhancing these vaccines' immunogenicity, stability, and delivery methods. Moreover, expanding our understanding of the interplay between these vaccines and the immune system will be crucial. We hope these insights will inspire and guide fellow researchers in the ongoing quest to combat picornavirus infections more effectively.